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Abstract   
The longer survival of patients with heart transplantation (HT) favors calcineurin inhibitor–related chronic kidney 
disease (CKD). It behoves to identify risk factors. At 14 Spanish centers, data on 1062 adult patients with HT (age 
59.2 ± 12.3 yr, 82.5% men) were collected at routine follow-up examinations. Glomerular filtration rate, GFR, was 
estimated using the four-variable MDRD equation, and moderate-or-severe renal dysfunction (MSRD) was defined as 
K/DOQI stage 3 CKD or worse. Time since transplant ranged from one month to 22 yr (mean 6.7 yr). At assessment, 
26.6% of patients were diabetic and 63.9% hypertensive; 53.9% were taking cyclosporine and 33.1% tacrolimus; and 
61.4% had MSRD. Among patients on cyclosporine or tacrolimus at assessment, multivariate logistic regression 
identified male sex (OR 0.44), pre- and post-HT creatinine (2.73 and 3.13 per mg/dL), age at transplant (1.06 per yr), 
time since transplant (1.05 per yr), and tacrolimus (0.65) as independent positive or negative predictors of MSRD. It 
is concluded that female sex, pre- and one-month post-HT serum creatinine, age at transplant, time since transplant, 
and immunosuppression with cyclosporine rather than tacrolimus may all be risk factors for development of 
CKD ≥ stage 3 by patients with HT. 
The life expectancy of patients with heart transplantation (HT) is steadily increasing. According to the 
ISHLT Registry report for 2008, the estimated median survival time among patients surviving the first yr 
after transplantation, calculated from data for 1982–2006, is 13 yr (1). Longer survival brings with it a 
greater risk of non-cardiac morbidities because of normal aging (such as diabetes), immunosuppression 
(such as neoplasia and infections), and adverse side effects of immunosuppressive therapy that do not 
derive directly from immunosuppression per se. In particular, the nephrotoxic effects of calcineurin 
inhibitors (CNI) have been of concern virtually since the introduction of cyclosporine (2), both on their 
own account and because of the cardiovascular and other non-renal pathological implications of renal 
dysfunction (3). Post-transplant chronic kidney disease (CKD) of K/DOQI (4) stage 4 or worse multiplies 
four-fold the death rate among all non-renal solid organ transplant patients (5), and the five-yr survival of 
patients with HT on dialysis for CKD is only half that of dialyzed patients with CKD with no organ graft 
(19% as against 40%) (6). The ISHLT-Registry-based Kaplan–Meier estimate of the intrinsic probability 
of an patient with HT who survives 13 yr developing severe renal dysfunction (serum creatinine 
> 2.5 mg/dL, dialysis or kidney transplant) exceeds 40% (1); the current actual prevalence of CKD of 
K/DOQI stage 3 or worse among Spanish patients with HT who survive more than 9.5 yr is 67% (7). 
The magnitude of the problem of post-transplant CKD makes it necessary to characterize patients at 
greatest risk, if only because this will facilitate preliminary evaluation of preventive strategies (8). Most 
studies that have investigated this issue have identified risk factors analogous to those of CKD of non-
transplant patients, including age, female sex, pre-transplant arterial hypertension and diabetes mellitus, 
together with pre-transplant renal dysfunction and post-operative acute kidney failure (3, 5). There has 
been less concord at least for patients with HT – regarding other possible risk factors, including serum 
triglycerides, original ischemic cardiopathy, blood urea and alkaline phosphatase, weight, body mass 
index, race, donor hypertension, and pre-transplant hepatitis C infection (1, 9–12). 
Here, we report risk factors for K/DOQI stage 3 CKD or worse that were identified by CAPRI, a 
cross-sectional observational study carried out in 14 Spanish heart transplant centers in late 2007 and 
early 2008 with the primary objective of determining the current prevalence of kidney dysfunction among 
Spanish patients with HT and risk factors therefore.  
Patients and methods 
Participants 
Between October 2007 and March 2008, each of 14 Spanish heart transplant centers fed the CAPRI 
database with relevant data on all first patients with HT aged > 18 who presented during a pre-defined 
three-month period for a routine follow-up examination more than 30 d post-transplant (informed consent 
was a further condition that gave rise to no exclusions). Data were recorded for a total of 1062 patients 
(82.5% males) with a mean age of 59.2 ± 12.3 yr and times since transplant ranging from one month to 
22.3 yr (mean 6.7 yr, SD 4.6 yr). Before transplant, 15.0% had received a diagnosis of diabetes mellitus 
(cf. 26.5% at the time of the study), 29.8% were hypertensive (cf. 64.1% at study time), and 2.0% were 
seropositive for hepatitis C. The original cardiopathy leading to HT was dilated cardiomyopathy in 
40.6%, and ischemic cardiomyopathy in 39.8%. Some 43.4% had suffered an episode of acute rejection 
of ISHLT grade 3A or worse in the first yr after transplant, and at the time of the study, 48.9% had been 
treated for cytomegalovirus infection. Table 1 lists details of immunosuppression at the time of the study. 
Table 1.   Immunosuppressive medication of 1062 Spanish patients with heart transplantation (HT) 
Immunosuppressant Prevalence (%) 
    
Calcineurin inhibitor   87.0 
 Cyclosporine  53.9  
 Tacrolimus  33.1  
Antimetabolite   81.3 
 Azathioprine  11.7  
 Mycophenolate  69.6  
  Mycophenolate mofetil 66.7   
  Sodium mycophenolate 2.9   
Steroids   68.3 
mTOR inhibitor   20.2 
 Sirolimus  5.9  
 Everolimus  14.3  
    
 
Outcome variable 
The outcome variable was K/DOQI stage 3 CKD or worse, hereinafter referred to for brevity as MSRD 
(moderate or severe renal dysfunction), and defined by the patients having an estimated glomerular 
filtration rate (eGFR) less than 60 mL/min per1.73 m2, or being on dialysis, or having undergone kidney 
transplant for post-HT kidney failure (4). 
Glomerular filtration rate was estimated using the four-variable MDRD equation: eGFR (mL/min per 
1.73 m2) = 186 ×  SCr−1.154 ×  Age−0.203 × Sex × Race; where SCr is serum creatinine in mg/dL, Age is in 
yr, Sex is 0.742 if female and 1 if male, and Race is 1.21 if black and 1 otherwise (4). 
Statistical analysis 
Patients with and without MSRD at the time of the study were compared with respect to relevant 
categorical variables by means of chi-squared tests, and with respect to continuous variables using 
Student’s t-tests following verification of distributional normality by Kolmogorov–Smirnov tests. 
Independent predictors of MSRD at the time of the study were identified by means of backward stepwise 
multivariate logistic regression analysis of the data for the 977 patients for whom data were available for 
all the eight variables initially included in the model, to wit, all except two of the non-medicational 
variables for which significant between-group differences had been detected in the univariate analyses 
(age at transplant; pre-transplant diabetes, hypertension, and serum creatinine; serum creatinine 30 d after 
transplant; and time since transplant – hypertension and diabetes at study time were omitted as redundant) 
plus sex and the occurrence of acute rejection of ISHLT grade ≥ 3A in the first yr post-transplant (these 
last two being included on clinical grounds; see the Discussion). Variables were dropped from the model 
if p < 0.1. To investigate the possible influence of tacrolimus (Tac) as against cyclosporine (CsA), two 
further multivariate logistic regressions were also performed on subsets of the 977, one including only the 
924 patients started on CsA or Tac after transplantation, and the other only the 853 patients taking CsA or 
Tac at the time of the study. The variables included in these two regressions were seven that emerged as 
significant or near significant in the analysis of 977 patient (see Results; these seven were forced to 
remain in the model as possible confounders) plus either Tac versus CsA after transplantation, or Tac 
versus CsA at the time of the study. All statistical calculations were performed using SPSS for Windows 
v. 16.0. The criterion for statistical significance was p < 0.05. 
Results 
The prevalence of MSRD in the study group at the time of the study was 61.4% (652/1062). Among the 
pre-transplant characteristics examined, the MSRD and non-MSRD groups differed significantly with 
respect to age at transplant (MSRD 55.5 ± 9.9 yr, non-MSRD 47.8 ± 13.3 yr; p < 0.001), serum creatinine 
(1.35 ± 0.63 vs. 1.13 ± 0.47 mg/dL; p < 0.001), diabetes (17.9% vs. 10.2%; p = 0.001), and arterial 
hypertension (34.5% vs. 22.2%; p < 0.001), but not with respect to sex or the original cardiopathy that 
had led to HT (Table 2). Among other variables of potential utility for prediction of MSRD, the MSRD 
and non-MSRD groups differed significantly with respect to serum creatinine 30 d after transplant 
(MSRD 1.35 ± 0.73, non-MSRD 1.06 ± 0.38; p < 0.001) and the time elapsed between transplant and 
study (7.1 ± 4.7 vs. 6.0 ± 4.4 yr; p < 0.001), but not with respect to seropositivity for hepatitis C virus, or 
treatment for cytomegalovirus infection, or the incidence of acute rejection ≥ ISHLT grade 3A in the first 
yr after transplant (Table 2). 
Table 2.   Comparisons with respect to non-medication variables between patients with heart transplantation (HT) with and without 
moderate or severe renal dysfunction (MSRD) at the time of the study 
Variable Non-MSRD MSRD p-value 
    
Pre-transplant    
Male sex 84.4 81.3 0.214 
Age at transplant (yr) 47.8 (13.3) 55.5 (9.9) <0.001 
Original cardiopathy    
Dilated cardiomyopathy 44.1 38.3 0.084 
Ischemic cardiomyopathy 35.4 42.6  
Others 20.4 19.0  
Serum creatinine (mg/dL) 1.13 (0.47) 1.35 (0.63) <0.001 
Diabetes mellitus 10.2 17.9 0.001 
Arterial hypertension 22.2 34.5 <0.001 
Post-transplant    
Serum creatinine 30 d post-HT (mg/dL) 1.06 (0.38) 1.35 (0.73) <0.001 
Hepatitis C virus 1.2 2.5 0.181 
Cytomegalovirus infection 45.7 50.9 0.101 
Acute rejection ≥ grade 3A in the first yr 40.4 45.4 0.127 
At the time of the study    
Arterial hypertension 54.6 70.0 <0.001 
Diabetes 20.2 30.5 <0.001 
Time since transplant (yr) 6.0 (4.4) 7.1 (4.7) <0.001 
    
 
Data are percentages, or means with standard deviations in parentheses. 
In both groups, the prevalences of both arterial hypertension and diabetes at the time of the study were 
about double what they had been before transplant, increasing the difference between the two groups with 
respect to these variables. 
There were also significant differences between the MSRD and non-MSRD groups as regards their 
immunosuppressive regimens, both at initiation of immunosuppression and at the time of the study; in 
particular, at both times, smaller proportions of the MSRD group received Tac (Table 3). Additionally, 
larger proportions of the MSRD group were started on CsA and azathioprine and a smaller proportion on 
mycophenolate; and at study time, the prevalence of immunosuppression with sirolimus or everolimus 
was greater in the MSRD group, and the prevalence of azathioprine was smaller (Table 3). 
  
Table 3.   Comparisons between patients with heart transplantation (HT) with and without MSRD at the time of the study with 
respect to immunosuppressive medication used for initiation of immunosuppression, and immunosuppressive medication at the time 
of the study 
Variable Non-MSRD MSRD p 
    
At initiation    
Induction with antibodies 77.8 81.4 0.156 
Steroids 95.9 97.2 0.222 
Cyclosporine 75.6 80.8 0.045 
Tacrolimus 19.5 13.5 0.01 
Azathioprine 34.9 43.1 0.008 
Mycophenolate 61.5 50.6 <0.001 
Sirolimus 1.7 1.7 1 
Everolimus 2.2 3.1 0.445 
At study time    
Steroids 65.4 70.1 0.119 
Cyclosporine 51.7 55.2 0.283 
Tacrolimus 38.0 30.1 0.007 
Azathioprine 14.9 9.7 0.011 
Mycophenolate 72.9 67.5 0.065 
Sirolimus 3.9 7.2 0.032 
Everolimus 11.0 16.4 0.015 
    
 
Data are given in percentages. 
The significant independent predictors of MSRD identified in the initial multivariate logistic 
regression analysis of data for 977 patients (see Patients and methods) were female sex, age at transplant, 
time since transplant, and serum creatinine before and 30 d after transplant (p ≤ 0.001 in all cases; odds 
ratios (ORs), and their 95% confidence intervals (CIs) are listed in Table 4). Additionally, pre-transplant 
diabetes (OR 1.49, 95% CI 0.97–2.29; p = 0.066) and acute rejection ≥ grade 3A in the first yr (OR 1.31, 
95% CI 0.98–1.77; p = 0.072) came near to statistical significance. When all these variables were 
adjusted in the multivariate analysis that included the variable Tac vs. CsA at institution of 
immunosuppression, Tac vs. CsA was not significant (OR 0.755, 95% CI 0.501–1.140; p = 0.182). 
However, in the analysis of data for 853 patients taking CsA or Tac at the time of the study, Tac vs. CsA 
emerged as a significant independent predictor alongside all the other variables except pre-transplant 
diabetes and acute rejection, Tac being less associated with MSRD than CsA (OR 0.65, 95% CI 0.46–
0.90; p = 0.011). 
Table 4.   Variables with significant or near-significant association with MSRD in a multivariate logistic regression in which the 
initial variables were those shown here plus pre-transplant hypertension 
Variable OR 95% CI p value 
    
Male sex 0.519 0.346 – 0.777 0.001 
Pre-transplant serum creatinine (per mg/dL) 2.022 1.375 – 2.972 <0.001 
Age at transplant (per yr) 1.060 1.046 – 1.074 <0.001 
Serum creatinine 30 d post-HT (per mg/dL) 4.025 2.588 – 6.260 <0.001 
Time since transplant (per yr) 1.077 1.043 – 1.113 <0.001 
Pre-transplant diabetes 1.494 0.974 – 2.292 0.066 
Acute rejection ≥ grade 3A in the first yr 1.314 0.976 – 1.768 0.072 
    
 
OR, odds ratio, CI, confidence interval. 
The analysis included data for the 977 patients for whom data were available for all eight variables. 
  
Suspecting, in view of the general evolution of immunosuppressive regimens, that this last result 
might be because of early patients with HT having received larger dosages of cyclosporine than later 
patients, we repeated this analysis including only the 633 patients treated after the introduction of 
tacrolimus 9 yrs before the study date, but the only noteworthy change in the results was that time since 
transplant was no longer a significant predictor; in particular, the influence of Tac vs. CsA was almost 
unaltered (OR 0.68, 95% CI 0.47–0.98; p = 0.038). 
Discussion 
The risk factors for post-HT MSRD identified in this work were female sex, age at transplant, time 
since transplant, serum creatinine before and 30 d after transplant, and current maintenance on CsA rather 
than Tac. These factors mostly coincide with those identified in other studies of renal dysfunction among 
patients with HT and other non-renal solid organ transplant patients. 
The variables of the initial models employed in the regression analyses from which these predictors 
emerged included sex and acute rejection in the first yr, in spite of these variables not having differed 
significantly between the MSRD and non-MSRD groups in the corresponding univariate analyses. Sex 
was included fundamentally because female sex has frequently emerged as a significant risk factor in 
other studies; and acute rejection in the first yr because of its probably having given rise to the 
maintenance of larger doses of CNI, which in this study would make it a confounder. 
Conversely, the multivariate analyses did not include immunosuppressive variables with respect to 
which the two groups had differed significantly in univariate analyses (with the exception of Tac vs. CsA 
in the last three multivariate analyses). Calcineurin inhibitors as a class were at first excluded because 
they are the root cause of post-transplant MSRD and were in any case initially administered to 95% of 
patients; while between-group differences in other immunosuppressants were regarded either as a 
consequence of concomitant differences in time since transplant and/or calcineurin inhibitor dosage or as 
a result of changes in therapy because of the detection of renal dysfunction (and hence not as risk factors). 
Thus, although the proportion of patients started post-operatively on azathioprine was larger in the MSRD 
than the non-MSRD group and the proportion started on mycophenolate smaller, we assume that this was 
partly because of the MSRD group having undergone transplantation at a slightly earlier date; and also, 
more decisively, to mycophenolate generally having been accompanied by lower doses of calcineurin 
inhibitors than azathioprine, as a consequence of which azathioprine-treated patients would be more 
likely to progress to MSRD (13). At the time of the study, the proportion of patients on azathioprine was 
smaller in the MSRD group, which we assume to have been because of the fact that for some yr, our 
centers, in view of our own experience (13) and the results of the IMPROVED study (14), have 
responded to renal dysfunction by switching patients from azathioprine to mycophenolate, with reduction 
or replacement of CNI. The greater prevalence of mTOR inhibitors in the MSRD group at study time is 
likewise attributable to their having been prescribed in response to the detection of renal dysfunction (15). 
By contrast, the inclusion of the variable Tac vs. CsA in the three final multivariate analyses is justified 
because in none of the 14 participating centers has it been standard practice to replace CsA with Tac in 
response to renal dysfunction. 
Age at transplant has emerged as a risk factor in numerous studies (1, 5, 11, 16–19), even though the 
definition of renal dysfunction has varied considerably, from serum creatinine > 1.5 mg/dL (16) to GFR 
< 20 mL/min per 1.73 m2 (19). Age is in fact expected to predict almost any GFR-based concept of renal 
dysfunction, since GFR in the general population aged > 30 falls by about 1 mL/min per 1.73 m2 per yr 
(4). Interestingly, age was not an independent predictor in two studies in which the criterion variable was 
end-stage renal disease (ESRD) (20, 21). 
As noted above, female sex is also a risk factor for renal dysfunction that has been observed in many 
studies (4, 12, 17, 18), and which patients with HT “inherit” from the general population, where GFR is 
said to be around 8% less in women than in men (4). In the only study we know in which male sex rather 
than female sex emerged as a risk factor (16), this finding may have been related to the criterion for renal 
dysfunction having been very lax (serum creatinine > 1.5 mg/dL) and/or to all patients having had normal 
pre-transplant serum creatinine values. 
Time since transplant is likewise expected to increase the risk of renal dysfunction, partly because it 
contributes to age, and partly because it implies longer exposure to CNI for patients taking these drugs. 
Another known risk factor for CKD – and for post-operative death (22) – is post-operative acute 
kidney injury (AKI), especially if renal replacement therapy is required for its reversal (5, 18). Whereas 
recovery from properly treated AKI is generally virtually total among non-transplant patients, it is 
hindered in transplant patients by immunosuppressive medication and by any functional 
underperformance by the transplanted organ (23). Post-operative AKI was not considered as such in the 
present study, but will no doubt have contributed to the influence of serum creatinine concentration 30 d 
post-HT, which must also reflect the reported influence of a sharp decline in renal function in the first 
three months after transplant (24). The emergence of pre-transplant serum creatinine as a risk factor 
independent of 30 d post-HT creatinine may also be due in part to the influence of the former on the 
incidence of post-operative AKI (22, 25). 
Although the calcineurin inhibitors Tac and CsA were not found to differ in their renal effects in two 
short-term (12–18-month) multicenter studies in which 314 patients were randomized to one or the other 
(26, 27), there is increasing evidence that Tac not only improves blood lipid profile, but is also less 
renoaggressive than CsA following HT, at least as regards stabilization or improvement of GFR and 
serum creatinine (5, 12, 28–31). This conclusion appears to be supported by the results of the present 
study (in which the mean time since transplant was 6.7 yr): Tac was used by a greater proportion of non-
MSRD than patients with MSRD both post-operatively and at the time of the study, and CsA by larger 
proportions of patients with MSRD than non-MSRD patients (Table 3); and Tac versus CsA at study time 
emerged as a significant predictor in the multivariate analyses in which it was included. Although it is not 
clear why Tac versus CsA at the institution of immunosuppression was not a significant predictor, this 
negative result may derive from Tac originally having been prescribed mainly to female patients – who 
are more prone to renal dysfunction – on account of the hirsutism associated with CsA (results not 
shown). 
The above results must of course be considered with caution owing to the cross-sectional nature of 
this study. In particular, it is difficult to judge the extent to which they may have been affected by 
selective survival; for example, selective survival may have led to such acknowledged risk factors as 
diabetes, hypertension, and hyperlipidemia not emerging as such in this study. Also, although a 
distinction was made between post-operative immunosuppression and immunosuppression at the time of 
the study, no attempt was made to take into account the time point at which conversion from CsA to Tac 
may have taken place, changes in other reno-relevant medication (immunosuppressives, anti-
hypertensives, etc.), or drug dosages or serum levels (though it is unlikely that generally recommended 
dosages can have been departed from). Nevertheless, none of the positive findings clashes with the recent 
literature in the field, and the lesser nephrotoxic risk of Tac at the time of the study emerged in spite of 
the above-noted greater prevalence of immunosuppression with Tac among female patients, who are more 
likely to progress to MSRD. 
In conclusion, in this cross-sectional study of 1062 patients with HT, female sex, age, and serum 
creatinine at transplant, serum creatinine a month after transplant, time since transplant, and current use of 
CsA rather than Tac all emerged as statistically independent predictors of K/DOQI chronic kidney disease 
of stage 3 or worse. These findings should be tested further in prospective longitudinal trials. 
Authorship 
Designed study: Juan F. Delgado and MG Crespo. Performed study and collected data: J. F. Delgado, M. 
G. Crespo-Leiro, Miguel A. Gómez-Sánchez, M. J. Paniagua, F. González, J. A. Vázquez, J. Fernández, 
D. Pascual, L. Almenar, L. Martínez, B. Díaz, E. Roig, J. Segovia, J. M. Arizón, I. Garrido, T. Blasco, J. 
López, V. Brossa and N. Manito. Analyzed data: Javier Muñiz. Wrote the paper: Juan F. Delgado. 
Funding sources 
Astellas Pharma (unrestricted grant), and the Spanish Ministry of Health and Consumer Affairs through 
the Carlos III Institute Cardiovascular Research Networks REDINSCOR (JFD, LA, LM-D, ER, JS, and 
IG) and RECAVA (MC-L, MP and JM). 
Acknowledgements 
We thank Ian-Charles Coleman for helpful criticism and for the English version of this article. This 
research was supported by an unrestricted grant from Astellas Pharma and by the Spanish Ministry of 
Health and Consumer Affairs through the Carlos III Institute Cardiovascular Research Networks 
REDINSCOR (JFD, LA, LM-D, ER, JS and IG) and RECAVA (MC-L, MP and JM). 
The Abstract was presented at the International Society for Heart and Lung Transplantation 29th 
Annual Meeting and Scientific Sessions, Paris (France), April 22-25th, 2009. 
  
Appendix 
The following institutions and researchers participated in the CAPRI study (listed in descending order of 
the number of patients enrolled). 
Complejo Hospitalario Universitario de A Coruña: Marisa Crespo Leiro, María J. Paniagua, Zulaika 
Grille, Carmen Naya, Victoria Prado. 
Hospital Universitario 12 de Octubre, Madrid: Juan F. Delgado, Miguel Angel Gómez Sánchez, Pilar 
Escribano, Nuria Ochoa, Marta Paradina y María Vicente. 
Hospital Universitario Marqués de Valdecilla, Santander: Francisco González- Vílchez, Jose A. Vázquez 
de Prada, Tamara García-Camarero, Miguel Llano. 
Hospital General Universitario Gregorio Marañón, Madrid: Juan Fernández-Yáñez, David Pascual 
Hernández, Jesús Palomo Álvarez. 
Hospital Universitario La Fe, Valencia: Luis Almenar, Luis Martínez-Dolz. 
Hospital Universitario Central de Asturias, Oviedo: Beatriz Díaz-Molina, Jose Luis Rodríguez Lambert. 
Hospital Clínic i Provincial, Barcelona: Eulalia Roig, Félix Pérez Villa. 
Clínica Puerta de Hierro, Madrid: Luis Alonso-Pulpón, Javier Segovia, Manuel Gómez Bueno. 
Hospital Universitario Reina Sofía, Córdoba: Jose M. Arizón, Juan Carlos Castillo Domínguez, Amador 
López Granados. 
Hospital Universitario Virgen de la Arrixaca, Murcia: Iris P. Garrido, Domingo A. Pascual Figal. 
Hospital Universitario Miguel Servet, Zaragoza: Teresa Blasco Peiró, Maria Luisa Sanz Julve. 
Hospital Clínico Universitario, Valladolid: Javier López Díaz, Luis de la Fuente Galán. Hospital de la 
Santa Creu i Sant Pau, Barcelona: Vicens Brossa, Sonia Mirabet Pérez. Hospital Universitario de 
Bellvitge, Barcelona: Nicolás Manito Lorite. 
Instituto de Ciencias de la Salud, Universidad de A Coruña: Javier Muñiz García. 
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